Business Description
Nxera Pharma Co Ltd
ISIN : JP3431300007
Share Class Description:
FRA:JSS: Ordinary SharesTotal Employee Number:
443Description
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.88 | |||||
Debt-to-EBITDA | -18.07 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.85 | |||||
Beneish M-Score | -1.14 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.3 | |||||
3-Year Book Growth Rate | -1.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.1 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.09 | |||||
9-Day RSI | 44.01 | |||||
14-Day RSI | 44.55 | |||||
3-1 Month Momentum % | -0.93 | |||||
6-1 Month Momentum % | 21 | |||||
12-1 Month Momentum % | 6.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.61 | |||||
Quick Ratio | 1.86 | |||||
Cash Ratio | 0.78 | |||||
Days Inventory | 441.48 | |||||
Days Sales Outstanding | 94.14 | |||||
Days Payable | 230.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.4 | |||||
Shareholder Yield % | 9.59 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.32 | |||||
Operating Margin % | -28.57 | |||||
Net Margin % | -42.31 | |||||
EBITDA Margin % | -10.43 | |||||
FCF Margin % | -35.05 | |||||
OCF Margin % | -16.59 | |||||
ROE % | -19.38 | |||||
ROA % | -8.92 | |||||
ROIC % | -6.48 | |||||
3-Year ROIIC % | -11.07 | |||||
ROC (Joel Greenblatt) % | -35.76 | |||||
ROCE % | -5.98 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 14.68 | |||||
PS Ratio | 2.82 | |||||
PB Ratio | 1.32 | |||||
EV-to-EBIT | -17.66 | |||||
EV-to-EBITDA | -42.72 | |||||
EV-to-Revenue | 4.47 | |||||
EV-to-Forward-Revenue | 17.37 | |||||
EV-to-FCF | -12.4 | |||||
Price-to-GF-Value | 0.73 | |||||
Price-to-Projected-FCF | 2.13 | |||||
Price-to-Median-PS-Value | 0.23 | |||||
Earnings Yield (Greenblatt) % | -5.67 | |||||
FCF Yield % | -12.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nxera Pharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 168.383 | ||
| EPS (TTM) (€) | -0.779 | ||
| Beta | 0.7426 | ||
| 3-Year Sharpe Ratio | -1.15 | ||
| 3-Year Sortino Ratio | -1.29 | ||
| Volatility % | 34.5 | ||
| 14-Day RSI | 44.55 | ||
| 14-Day ATR (€) | 0.108606 | ||
| 20-Day SMA (€) | 5.1715 | ||
| 12-1 Month Momentum % | 6.85 | ||
| 52-Week Range (€) | 4.04 - 6.55 | ||
| Shares Outstanding (Mil) | 91.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nxera Pharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nxera Pharma Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nxera Pharma Co Ltd Frequently Asked Questions
What is Nxera Pharma Co Ltd(FRA:JSS)'s stock price today?
The current price of FRA:JSS is €5.10. The 52 week high of FRA:JSS is €6.55 and 52 week low is €4.04.
When is next earnings date of Nxera Pharma Co Ltd(FRA:JSS)?
The next earnings date of Nxera Pharma Co Ltd(FRA:JSS) is .
Does Nxera Pharma Co Ltd(FRA:JSS) pay dividends? If so, how much?
Nxera Pharma Co Ltd(FRA:JSS) does not pay dividend.
Press Release
Articles on Nxera Pharma Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers